Abstract
Clinical Neuroscience The formation of beta-amyloid plaques, known as Aβ aggregates, is implicated as a driving force of Alzheimer's disease. Vendruscolo et al. applied chemical kinetic approaches to identify bexarotene, an anticancer drug that selectively activates retinoid X receptor, as a molecule that can alter Aβ aggregation in vitro and in a C. elegans model. The inhibition of Aβ aggregate nucleation by bexarotene may therefore reduce the risk of development and progression of Alzheimer's disease and other similar neurodegenerative disorders. Sci. Adv. 2 , 10.1126.sciadv.01244 (2016).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
